SYNCOM/SE/2023-24 14th February, 2024

Online filing at: www.listing.bseindia.com and

https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To, To,
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Tower, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex, Bandra (E),
Mumbai (M.H.) 400 001 Mumbai- 400051
BSE CODE:524470 NSE SYMBOL: SYNCOMF

Subject: Submission of the Un-Audited Standalone and Consolidated Financial Results along
with Limited Review Report thereon for the Quarter and Nine Months ended on 31st December,
2023 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir/Ma’am,

This is in continuation of our letter no. SYNCOM/SE/2023-24 dated 6th February, 2024 regarding
intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-
Audited Financial Results for the Quarter and Nine Months ended on 31st December, 2023.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to the following:

1. Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter
and Nine Months ended on 31st December, 2023;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the
company for the Quarter and Nine Months ended on 31st December, 2023.
which was considered and approved by the Board at their 5/2023-24 Meeting held on Wednesday, the
14th February, 2024.

The meeting of the board of directors was commenced at 11:00 AM and concluded at 05:20.PM.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time
and same shall also be hosted at the website of the company www.sfil.in.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular)
newspaper in the prescribed format for that purpose.

You are requested to take on record the above said Standalone and Consolidated Un-Audited
Financial Results along with Limited Review Report for your reference and record.
Thanking You,
Yours Faithfully,
For, SYNCOM FORMULATIONS (INDIA) LIMITED
VAISHALI Digitally signed by
VAISHALI AGRAWAL

AGRAWAL Date: 2024.02.14

17:13:20 +05'30'

CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER
Encl: Standalone and Consolidated Un-Audited Financial Results and Limited Review Report.
SANJAY MEHTA & ASSOGIATES 338, Saket Nagar, lndore - 452 018 (M.P.)
Phone : 0731-2563625, 4274391,94250 62964
Ch artered Accountants
E-mail : [email protected]

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Ninth
Month ended 3l" December,2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations,
20r5
To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of

SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"), for the period ended
December. 31.2023 ("the Statement"), attached herewith, being submitted by the Company
pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,20l5, as
amended including relevant circular issued by tlre SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been
approved by the Company's Board of Directors, has been prepared in accordance with the
recognition and measurement principles laid down in the Indian Accounting Standard 34
Interirn Financial Reporting" ("lND AS 34"), prescribed under Section 133 of the Cornpanies
Act, 2013" and other Accounting principles generally accepted in India and in compliance with
the Regulatiort 33 of the SEBI (LODR) Regulations,2015, as amended, including relevant
circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these
Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review
Errgagements (SRE) 2410, "Ret,iew o.f Interim Financial lffirmation performed by the
Independent Auditor o.f the Entity", issued by the Institute of Chartered Accountants of India.
This standard requires that we plan and perform the review to obtain moderate assurance as to
whether the flnancial statements are fiee of material misstatement. A review is limited
prirnarily to inquiries of company personnel and analytical procedures applied to financial data
and thus provide less assurance than an audit. We have not performed an audit and accordingly.
we do not express an audit opinion.

Based on our review conducted as stated above, nothirrg has come to our attention that causes
us to believe tirat the accompanying Statement, prepared in accordance with applicable
Accountittg Standards and other recognized accounting practices and policies has not disclosed
the infbrmation required to be disclosed in terms of Regulation 33 of the SEBI (Listing
Obligations and Disclosures Requirenrents) Regulations, 20l5,including the manner in which
it is io be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates

Chartered ntants
FRN: 01 I

Place: lndore
Date: l,lth February, 2024 A Manish Mitt
(Partner) i
M. No. 079452
U DIN : 2407 9152BJZYSX8939
F- SYNCOM FORMULATTONS (rNDrA) LTMTTED
Regd.Off:- T,Niraj lndustrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Meil:- [email protected], Website:- www.sfil.in, CIN :- 124239MH1988P1C047759
STANDALONE UNAUOITED FINANCIAL RESULTS FOR THE QUARTERYNINE MONTHS ENDED 3.IST DECEMBER, 2023
Rs. ln Lacs except EPS
s. Particulars Quarter Ended Nine months Year Ended
No.
31.12-2023 30-09-2023 31-12-2022 31-12-2023 31-12-2022 31{3-2023
Unaudited Unaudited UnauditeU Unaudited Unaudited Audited
,l
(evenue rrom uperatons
6334,22 6238.68 5738.29 18509.33 16327.47 22161.39
2 )ther lncome 434.89 400,35 1 97.85 1022.98 783.01 [email protected]
total lncome(1+2) 6769.1 1 6639.03 5936.1 4 1 9532.31 17110.48 23925.34
4 EXPENSES
( a ) Cost of materials consumed 3774.65 3325.08 2199.90 9365.04 7391.22 9946.06
( b ) Purchases of Stock-in-Trade 398.25 819.89 1094.05 2132.22 2939.98 4261.'14
( c ) Changes in inventories of finished goods, Stock-in- Trade
and work-in-progress (279.99) (308.60) 183.32 (198.06, 10't.52 5.03
( d ) Employee benefits expense
973.63 900.1 0 725.67 2636.54 1 866.79 2586.56
(e)Financecosts 08.1 6 107.57
1 7'1.70 327.90 183.83 313.02
( f ) Depreciation and amortizalion expense
144.58 87.88 120.15 342.46 337.1 5 453.93
(g)Otherexpenses 787 .71 893.03 944.79 2668.67 2660.42 3704.28
Totalexpenses(4) 5906.99 5824.95 5339.58 't7274.77 1 5480.91 21270.02
5 Pronu(loss) before oxcoptlonal ltams and tax (3.4) 862.12 8t 4.08 596.56 2257.54 1629.57 2655.32
6 Exceptional ltems (2.39 0.00 0.00 (2.3s) 0.00 1.33
7 Profiu(loss) before tax ( 5 .6 ) 859.73 814.08 596.56 2255.',t5 1 629.57 2656.65
I Iax expense:
,'1) Current tax 207.81 148.41 161 .00 516.52 406.00 664.84
.2) Deferred tax 9.85 45.12 21.O5 51.16 63.1 5 (15.26',
9 )rofit (Loss) for th6 period from continuing operations (7-8)
642.07 620.55 414.51 1687.47 1160.42 2007.07
10 )rofiu(loss) from disconlinued operations U.UU U.UU U.W
11 fax expense of discontinued operations 0,00 0.00 0.00 0.00 0.00 0.@
12 rrofiu(loss) from Discontinued operations (after tax) (10-1 1)
0.00 0.00 0.00 0.00 0.00 0.@
'13 >rofiu(loss) for the period ( 9 + 12 642.07 620.55 414.51 1687.47 1160.42 2007.07
)
14 Other Comprehensive lncome
A(l)ltems that will not be reclassified to profit or loss
0.00 0.00 0.00 0.00 0.00 000
lll) lncome tax relating to items that will not be reclassified tc
crofit or loss 0.00 0.00 0.00 0.00 0.00 0.00
3 (l) ltems that wrll be reclassified to proflt or loss 124.34
185.71 111.57 516.82 147.51 196.36
lll) lncome tax relating to items that will be reclassifled to profil
lr loss 0.00 0.00 0.00 0.00 0.00 0.00
15 fotal Compr€hensive lncome for the perlod (Xlll+Xlv)
lcomprlslng Profit (Loss) and Other Comprohenslvc
ncome for ths perlod) 827.78 744.89 526.08 2204.29 1307.93 2203.43
16 Paid up Share Capital of the Company (Face Value 1/-) 9400.00 9400.00 9400.00 9400.00 9400.00 9400 00
17 Reserves excluding revaluation reserves 0.00 0.00 0.00 16201.47
0.00 0.00
18 Earnings per equity share (for continuing operation):
(1) Basic 0.09 0,08 0.06 0.23 0.14 0.24
(2) Diluted 0.09 0.08 0.06 0.23 0.14 o.24
19 Earnings per equity share (for discontinued operation):
(1) Basrc 000 0.00 0.00 0.00 0.00 0.00
(2) Diluted 0.00 0.00 0.00 0.00 0.00 0.00
20 Eamings per equiiy share (for discontinued & continuing
operations)
(1) Basic 0.09 0.08 0.06 0.23 0.14 o.24
(2) Oiluled 0.09 0.08 0.06 o.23 0.14 0.24

Place: lndore
Oate:1410212024
=$%.
il]tQr, Syncom Formulations (lndia) Limited

tr Qvlo-r9
I<
,/n+//
l, Chairman & Wholetime Director
DtN: ooo23o5o
 4
SYNCOM FORMULATIONS (lNDlA) LIMITED
Regd.Off:- T.Niraj lndusmal Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 25&257. Sector - 1, Pithampur, Dist; Dh8tr454775
E Mail: finane@sfil,in, websitei www.sfil.in, clN :- 124239MH'1988PLC047759

SreruO*ONE STATEMENT OF SEGrvtrNr WtSe REVENUE, RESULTS ALONG WITH QUARTERLY /NINE MONTHS ENDED 31.12.23 UNAUDITEO RESULTS
Rs. ln Lacs
Quarter Ended NINE MONTHS Previous Year
Ended
S. No. Particulars 31-12-2023 30-09-2023 31-12-2022 31-12-2023 31-12-2022 31{3-2023
Unaudited Unaudited Unaudited lJnaudited Unaudited Audited

1 Sogmont Rovonue
a) Pharmaceuti€ls Orugs & Formulstions 6554.8( 6255.8( 4615.4: 18370.09 1 5r05.6i 21037.61.

b) Trading of Commodities 1 14.3( 286.0r 1237 .54 857.41 1749.3€ 2552.4

99.9i 97.',t' 83.1t 304.81 ?55.47 335.2r
c) Renting of Property
Total Segment Rovenuo 6769.'l 6639.0: 5936.1,( 19532.3 17110.4t 23925.v

Less: lnter Segment Revenue 0.0( 0.0( 0.0( 0.0( 0.0( 0.0(

Total lncom6 6769.1 6639.0: 5936.1( 19532.3 110.48 23925.31

2 Sogment Results Prorit(+yLoss(-) before tar

and interest from sach segmgnt
a) Pharmaceuticls Drugs & Formulations 873.6i 823.7( 583.92 2293.3( 1538.7t 2620.14

b) Trading of Commodities -1.'l 1 5.3{ 'I .1t -1.4t 19.1t 32.4?

c) Renting of Property 95.3r 92.5i 83.1t 291 .1 t 255.41 31 7.1 C

Total Profit bofore tax and lntersst 967.8! 921.6t 668.2( 2583.0t 3.4( 2969.67

Less i) lnterest 108.1( 107.5i 71.7C 327.9( 183.8: 313.0'

r) Other Un-allocable Expenditure 0.0( 0.0( 0.0( 0.0( 0.0( 0.0(

596.5( 2255.1 't629.5i 2656.51
Prolit berore tar 859.71 E14.01

3 (Segment Asset-Segment Liabilitios)

Segment Asset
a) Phamaceutic€ls Drugs & Formulations 36167.1i 34624.2! 331 63.2r 36'167.1i 331 63.2( 32m2.0C

b) Trading of Commodities 41.2i 1063.71 0.0( 41.2i 0.0( 95E.8S

c) Renting of Prope(y 4740.61 4733.41 4733.4! 4740.61 4733.44 4733.,15

Total S€gment Assot 40949.0: 4042',t.41 37896.7' 40949.0: 37895.7 37694.3!

Un-allocable Assets
Net Ssgment Assot 40949.0: 40421.41 37896.7' 40949.0: 37896.71 3769r1.3S

Ssgment Liabilities
a) Pharmaceuticals Drugs & Formulations 12936.7( 13155.03 13032.41 12936.7( 13032.4/ I 1749.5€

b) Trading of Commodities 52.1', 131.3t 0.0( 52.1' 0.0( 179.91

163,9' '163.4r 157.71 163.9' 157.71 163.4,4

c) Renting of Property
Total Segmont Llabilities 1 31 52.E' 13449,E! 13190.2i 1 3 1 52.8', 13190.2: 12092.91

0.0( 0.0( 0.0( 0.0( 0.0(

Un-allocable Llabilities 0.0(
't 2092.91
Net Segment Liabilities 13152.E 1 3449.8I 1 3 t 90.2: 13152.8 1 31 90.2:

Notes:-
1 The above results were reviewed by the Audil Committee and approved by the Board at its meeting neu on 1410A2024.

2013 read with Companies (lndian Accounting Standards) Rules 2015 as amondsd from time lo time. J

given as required.
4 As required under Regutation 33 of SEB| (LODR) Regulations, 201 5 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31 st
December, 2023. The report does not have any impact on the above rosulls and notes which needs explanalion.
5 Provious period tigures have been regrouped/roclassified wherever necessary to conlirm to this Period classificstion.
6 The compsny has generated (From Fy-202G21 loFY-2022-23) R3. 1035.76 Lakhs b€ing the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to
15,93,47,820 equity shares of Rs. 1/- each issued at e premium of Rs. 1.53 p€r share aggregaling Rs. 4031.50 L8khs. Out of which the company has already utilized the amount of

31st Dec 2023 and necessary report towards as roquired under regulation 32 being tiled to the BSE Ltd. Seperately

Place: lndore

%
om Formulations (lndia) Limited
Dale:1410212024
/r,'illvqB\
{,i' \Tl
et ]i
ta'\.-
(t0ruuolz
i-q Chairman & Wholetime Directot
DIN: 0002305(
SAXJAY MEHTA & ASSOCIATES 338, Saket Nagal lndore - 452 018 (M.P.)
Phone : O73t-2563625, 427439t,94250 62964
ChrteredAccountants
E-mail ; [email protected]

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Nine Months
ended 3l't December,2023 pursuant to Regulation 33 of the SBBI (LODR) Regulations,20l5

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
lndore (M.P.)

l. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results

of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the
Parent and its subsidiaries together ref'erred to as "the Group"), fbr the period ended December,
31, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to
the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended
including relevant circular issued by the SEBI from time to time.

2. This statement which is the responsibility of the Company's Management and has been
approved by the Company's Board of Directors, has been prepared in accordance with the
recognition and measurement principles laid down in the lndian Accounting Standard 34
lnterim Financial Reporting" ("lND AS 34"), prescribed under Section 133 of the Companies
Act, 2013, and other Accounting principles generally accepted in India and in compliance with
the Regulation 33 of the SEBI (LODR) Regulations,20l5, as amended, including relevant
circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these
Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review
Engagements (SRE) 2410, "Review of Interim Finoncial Information perfctrmed by the
Independent Auditor o/'the Entity", issued by the Institute of Chartered Accountants of India.
This standard recluires that we plan and perform the review to obtain moderate assurance as to
whether the flnancial statements are fiee of material misstatement. A review is limited primarily
to inquiries of oompany personnel and analytical procedures applied to financial data and thus
provide less assurance than an audit. We have not performed an audit and accordingly, we do
not express an audit opinion.

4. The Statement includes the results of the lbllowing entity:

S. No. Name of the Company Relationship with the Holding

Company
l. Sante Biotech Pr,t. Ltd. Whollv Owned Subsidiary
2 Synmex Pharma Pvt. Ltd Wholly Owned Subsidiary
J. Vincit Biotech International Pvt. Ltd. Wholly Owned Subsidiary
 Based on our review conducted as stated above, nothing has come to our attention that causes
us to believe that the accompanying Statement, prepared in accordance with applicable
Accounting Standards and other recognized accounting practices and policies has not disclosed
the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing
Obligations and Disclosures Requirements) Regulations,20l5,including the manner in which
it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates

Chartered Accountants

Place: Indore
Date: l4tr' February, 2024
(Partner)
M. No. 079452
UDIN : 2407 9 452BJZY SY 6937
 ULATIONS (lNDlA) LIMITED
Regd.Off:-T,NirajlndustrialEstato,OffMahakaliCavesRoad,Andheri(E)Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www sfil.in, CIN i 124239MH1988P1C047759

COI.ISOUiOETED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED

31S I UEUEMts'EI{ ' ZUZJ
Rs. ln Lacs except EPS
Quarter Ended Nine months Year tndeo
S. Particulars
No.
31-12-2023 30-09-2023 31-12-2022 3',t-12-2023 3'.t-12-2022 31{3-2023
Unaudited Unaudited Unaudited Unaudited Unaudited Audited

1 Revenue lrom Operations 6513.95 6383.89 5738.29 18881.42 1A327.47 22425.4?

455.54 399.74 197.85 1042.75 783.01 1459.99

2 Cther lncome
3 Iotallncome(1 +2) 6969.49 6783.63 5936.14 19924.17 '17110.48 23885.41

4 :XPENSES
3774.65 3325.08 2199.90 9365.04 7391.22 9946.06
a ) Cost of materials consumed
450.1 837.1 1 1094.05 2208.64 2939.98 4261.14
b ) Purchases of Stock-in-Trade 1

c ) Changes in inventories of finished goods, Stock-in- Trad€

(37.611
(271.89) (251.75) 183.32 (155.42) 101.52
tnd work-in-progress
d ) Employee benefits exPense 973.63 900.10 725.67 2636.54 1 866.79 2586.56

e ) Finance costs 108.16 107.57 71.70 327.90 183.83 313.10

f ) Depreciation and amorlization expense 144.58 87.88 120.15 342.46 337.1 5 453.93

851.74 932.73 944.82 2804.32 2661.1 3 3706.30

,g)Otherexpenses
fotalexpenses(4) 6030.98 5938.72 5339.61 1 7529.48 I 5481.62 21229.48

5 @masndtax(3'41 938.51 844.91 596.54 2394.69 1628.86 2655.93

6 Exceptional ltems (2.39 0.m 0.m (2.3s) 0.00 1.33

936.r 2 844.91 595.54 2392.30 1 628.86 2657.26

7 Prof'U(loss) before tax ( 5 - 6 )
8 Tax expense:
226.10 11€.62 161.00 550.1 7 406.00 665.,|s
(1 ) Current tax (1s.261
(2) Defened tax 9.85 45.12 21.05 51.16 63.15

9 profit (t-oss) toi the period from continulng operations (7{}

700.'17 651.17 414.49 1 790.97 1 159.71 2007.07

)rofiu(loss) from discontinued operations u.w u.w u.w u.uu

10
0.00 0.m 0.00 0.00 0.00 0.00
11 fax expense of disconlinued operalions
12 ,rofiu(loss) trom oiscontinued operations (aner tax) ( lG1 1 )
0.00 0.m 0.@ 0.00 0.00 0.00

700.,l 7 651.1 7 .114.49 790.97 1159.71 2007.07

period ( 9 + 12 1
13 "rotiu(toss) toi tne )
't4 Jther Comprehensive lncome
q(i)ltems that will not be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00

!i) lncome tax relating to items that will not be reclassified tc

0.00 0.00 0.00 0.00 0.00 0.00
crofit or loss
B (l) ltems that will be reclassified to profit or loss 185.71 124.34 111.57 516.82 147.51 196.36

(li) lncome tax relating to items that will be reclassified to profi

0.00 0.00 0.00 0.00 0.00 0.00
cr loss
15 iotaf-omprehenslve lncome for the porlod (xlll+XlV
Comprlslng Profit (Loss) 8nd Othor Comprehenslvc
885.88 775.51 526.06 2307.79 1307.22 2203.43
ncome for tho Period)
raid up Share Capital of the Company (Face Value 1^) 9400.00 9400.00 9400.00 9400.00 9400.00 9400.00
16
0.00 0.00 16201.47
17 ieseNes excluding revalualion reserves 0.00 0.00 0.00
l6 :arnings per equity share (for continuing operation):
0.09 0.08 0.06 0.25 0.14 o.24
i1) Basic
0.09 008 0.06 o.25 0.14 0.24
12) Diluted
'19 :arnings per equity share (for discontinued operation):
0.00 0.00 0.00 0.00 0.00 0.00
l1) Basic
0.00 0.00 0.00 0.00 0.00 0.00
(2) Diluled
20 Earnings per equily share (for discontinued & continuin€
cperations)
0.09 0.08 0.06 0.25 0.14 0.24
(1) Basic 0.14 o.24
0.09 0.08 0.06 0.25
12) Diluted

Place: lndore
Oale: ',410212024

;:,\ / a-ll Chairman & wholetimo Director

Ai>-4^""Y
S.. /r
DrN: ooo23o5(
 Svrucoru FoRMULATIoNS (lNDlA) LlMlrED
Rsgd.Off: T,Niraj lndustrial Estate,Off Mahakali Cavos Road,Andheri (E) Mumbai-400093
Worksi 256-257, Sector - 'l, Pithampur, Disi: Dhar-454775
E Mailr [email protected], Website: ww.sfil.in, CIN :- 124239MH'1988P1C047759

MONTHS ENDED 31/1212023 UNAUDITED RESULTS

CONSOLIDATEO STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY/NINE

Pharmaceuticals Drugs & Formulations

Trading of Commoditios
Renting of Property

Results Profi t(+)/Loss(-) bofore tax

Phamaceuti€ls Drugs & Formulstions

Trading of Commodities
Renting of Property

Pharmaceuticals 0rugs & Formulations

Trading of Commodilies

Renting of Prop€rty

1 1838.21
Pharmaceuticals Drugs & Formulations
179.91
Trading of Commodities
Renting of Property

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held o 1410212024

ZO13 reed with Companios (lndian Accounting Standards) Rules 2015 as amended from lime to time.

given as required.
been completed for the quarter/nine months ended on 31st
4 As required under Regulation 33 of sEBl (LoDR) Regulations, 2015 the limited roview by the statutory Auditors have
Ddcember, 2023. The-report does nol have any impact on the above results and notes which needs explanation.
period classilication.
5 previous period figures have been regrouped/reclassilied wherever necessary lo confirm lo this

6 The company has generated (Frcm Fy-2020-21

to 2022-29) Rs. 1 035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 1 5,93,47,820 warrants lo
1 5,93,47,g20 equity shares of Rs. 1/- each issued at a
premium of Rs. 1 .53 per sharJ aggregating Rs. 4031.50 Lakhs. out of which the company has already utilized the amount of

31 sl Dec 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately

L/rt\Eor, Syncom Formulations (lndia) Limited

--:.'r^\^z-6. ,-'-